Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis

Journal of Infection

Volumn 70, Issue 6, 2015, Pages 609-615

  Vergidis, Paschalis ^a   Schmidt Malan, Suzannah M ^a   Mandrekar, Jayawant N ^a   Steckelberg, James M ^a   Patel, Robin ^a  

^a MAYO CLINIC   (United States)

Author keywords

Osteomyelitis; Rifampin; Staphylococcus aureus; Tigecycline; Vancomycin

Indexed keywords

OXACILLIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; BACTERIAL COUNT; CHRONIC OSTEOMYELITIS; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FOREIGN BODY; FRACTURE; LOADING DRUG DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; RAT; TIBIA; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; HUMAN; METHICILLIN RESISTANCE; MICROBIOLOGY; OSTEOMYELITIS; STAPHYLOCOCCUS INFECTION; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MALE; METHICILLIN; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; OSTEOMYELITIS; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TIGECYCLINE; VANCOMYCIN;

EID: 84929133574     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.12.016     Document Type: Article

References (21)

1. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54:755-771.
2. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
3. Osmon D.R., Berbari E.F., Berendt A.R., Lew D., Zimmerli W., Steckelberg J.M., et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:e1-e25.
4. Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Societe de Pathologie Infectieuse de Langue Francaise. Med Mal Infect 2010, 40:185-211.
5. Esposito S., Leone S., Bassetti M., et al. Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 2009, 37:478-496.
6. Kandemir O., Oztuna V., Colak M., Akdag A., Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008, 20:53-57.
7. Yin L.Y., Lazzarini L., Li F., Stevens C.M., Calhoun J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002.
8. CLSI Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2009, Approved standard - Eight edition. CLSI document M07-A8, Vol. 29 No 2, Clinical and Laboratory Standards Institute, Wayne, PA.
9. CLSI Methods for determining bactericidal activity of antimicrobial agents 1999, Approved guideline. CLSI document M26-A, Vol. 19 No 18, Clinical and Laboratory Standards Institute, Wayne, PA.
10. Vergidis P., Rouse M.S., Euba G., Karau M.J., Schmidt S.M., Mandrekar J.N., et al. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob Agents Chemother 2011, 55:1182-1186.
11. Rouse M.S., Piper K.E., Jacobson M., Jacofsky D.J., Steckelberg J.M., Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006, 57:301-305.
12. Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279:1537-1541.
13. Lefebvre M., Jacqueline C., Amador G., Le Mabecque V., Miegeille A., Potel G., et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010, 36:542-544.
14. Tombs N.L. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology. San Francisco, CA 1999, abstract 413, p 302.
15. Tygacil. [package insert] 2011, Wyeth Pharmaceuticals Inc, Philadelphia, PA, revised.
16. Ambrose P.G., Meagher A.K., Passarell J.A., Van Wart S.A., Cirincione B.B., Bhavnani S.M., et al. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009, 63:155-159.
17. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
18. Ramirez J., Dartois N., Gandjini H., Yan J.L., Korth-Bradley J., McGovern P.C. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013, 57:1756-1762.
19. Rybak M.J., Lomaestro B.M., Rotschafer J.C., Moellening R.C., Craig W.A., Billeter M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-system Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
20. Albrecht L.M., Rybak M.J., Warbasse L.H., Edwards D.J. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. Dicp 1991, 25:713-715.
21. Hope R., Mushtaq S., James D., Pllana T., Warner M., Livermore D.M. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK. J Antimicrob Chemother 2010, 65:2602-2609.